Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?
Language English Country United States Media print-electronic
Document type Letter, Research Support, Non-U.S. Gov't
PubMed
37449465
DOI
10.1002/ajh.27022
Knihovny.cz E-resources
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma * drug therapy genetics MeSH
- Fusion Proteins, bcr-abl genetics MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Fusion Proteins, bcr-abl MeSH
See more in PubMed
Short NJ, Jabbour E, Macaron W, et al. Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. Published online May 15, 2023. https://doi.org/10.1002/ajh.26949
Zaliova M, Fronkova E, Krejcikova K, et al. Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring. Leukemia. 2009;23(5):944-951.
Hovorkova L, Zaliova M, Venn NC, et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood. 2017;129(20):2771-2781.
Zuna J, Hovorkova L, Krotka J, et al. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia. 2022;36(12):2793-2801.
Cazzaniga G, De Lorenzo P, Alten J, et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica. 2018;103(1):107-115.
